Norgine Expands Rare Disease Portfolio with Theravia Acquisition
Deal News | Apr 15, 2025 | PR Newswire Cision Norgine
Norgine, a specialty pharmaceutical company, has announced its acquisition of Theravia, an international pharma company specializing in rare and severe diseases. Purchased from Mérieux Equity Partners, the acquisition bolsters Norgine's portfolio of rare disease treatments aimed at enhancing its long-term growth strategy. This acquisition affirms Norgine's position as a premier partner for cutting-edge rare disease medications in Europe. Theravia's products, such as SIKLOS® for sickle cell disease and ORPHACOL® for genetic bile production disorders, complement Norgine's existing product range. The move also strategically positions Norgine for future growth through additional acquisitions and licensing agreements. The finalization of the deal awaits regulatory approvals.
Sectors
- Pharmaceuticals
- Healthcare
- Private Equity
Geography
- France – Theravia is based in France, and Mérieux Equity Partners, which sold Theravia, is also a French-based investment firm.
- Europe – The transaction highlights Norgine's aim to expand its presence in the European market for rare diseases.
Industry
- Pharmaceuticals – The article discusses the acquisition of a pharmaceutical company, Theravia, by another pharmaceutical company, Norgine, focusing on rare disease treatments.
- Healthcare – Both companies involved in the acquisition deal operate within the healthcare sector, delivering specialized medications for rare and severe diseases.
- Private Equity – Mérieux Equity Partners, a private equity firm, is involved as the selling company in the acquisition of Theravia by Norgine.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Norgine | Buyer | Company | A pharmaceutical company focused on specialty and consumer healthcare, now acquiring Theravia to boost its rare disease portfolio. |
| Theravia | Target company | Company | An international pharma company specializing in rare diseases, known for products like SIKLOS® and ORPHACOL®. |
| Mérieux Equity Partners | Vendor | Company | A French investment firm specialized in the healthcare sector, selling Theravia to Norgine. |
| Fennec Pharma | Other Company | Company | Partner company with existing agreements with Norgine for the PEDMARQSI® product. |
| X4 Pharma | Other Company | Company | Partner company working with Norgine on the mavorixafor product. |